Macular edema - Rationale for therapy

Developments in Ophthalmology

Volumn 47, Issue , 2010, Pages 49-58

  Wolfensberger, Thomas J ^a   Gregor, Zdenek J ^b  

^a UNIVERSITY OF LAUSANNE   (Switzerland)

^b MOORFIELDS EYE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CARBONATE DEHYDRATASE INHIBITOR; GLUCOCORTICOID; PROSTAGLANDIN RECEPTOR BLOCKING AGENT; PROSTAGLANDIN SYNTHASE INHIBITOR; PROTEIN KINASE C; VASCULOTROPIN A;

ARTICLE; BLOOD RETINA BARRIER; DRUG ANTAGONISM; DRUG EFFECT; HUMAN; METABOLISM; METHODOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; RETINA MACULA EDEMA; TREATMENT OUTCOME; VITRECTOMY;

BLOOD-RETINAL BARRIER; CARBONIC ANHYDRASE INHIBITORS; CYCLOOXYGENASE INHIBITORS; GLUCOCORTICOIDS; HUMANS; MACULAR EDEMA; PROSTAGLANDIN ANTAGONISTS; PROTEIN KINASE C; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VITRECTOMY;

EID: 84925969039     PISSN: 02503751     EISSN: 16622790     Source Type: Book Series    
DOI: 10.1159/000320073     Document Type: Article

References (69)

1. Tranos PG, Wickremasinghe SS, Stangos NT, Topouzis F, Tsinopoulos I, Pavesio CE: Macular edema. Surv Ophthalmol 2004;49:470-490.
2. Stefánsson E: Physiology of vitreous surgery. Graefes Arch Clin Exp Ophthalmol 2009;247:147-163.
3. Gillies MC, Su T, Stayt J, Simpson JM, Naidoo D, Salonikas C: Effect of high glucose on permeability of retinal capillary endothelium in vitro. Invest Ophthalmol Vis Sci 1997;38:635-642.
4. Gardner TW, Gabbay RA: Diabetes and obesity: a challenge for every ophthalmologist. Arch Ophthalmol 2009;127:328-329.
5. Aiello LP, Cahill MT, Wong JS: Systemic considerations in the management of diabetic retinopathy. Am J Ophthalmol 2001;132:760-776.
6. Liew G, Mitchell P, Wong TY: Systemic management of diabetic retinopathy. BMJ 2009;338:b441.
7. Colin J: The role of NSAIDs in the management of postoperative ophthalmic inflammation. Drugs 2007;67:1291-308.
8. Ku EC, Lee W, Kothari HV, Scholer DW: Effect of diclofenac sodium on the arachidonic acid cascade. Am J Med 1986;80:18-23.
9. Bialek S, Quong JN, Yu K, Miller SS: Nonsteroidal anti-inflammatory drugs alter chloride and fluid transport in bovine retinal pigment epithelium. Am J Physiol 1996;270:C1175-C1189.
10. Wolfensberger TJ, Herbort CP: Treatment of cystoid macular edema with non-steroidal anti-inflammatory drugs and corticosteroids. Doc Ophthalmol 1999;97:381-386.
11. Flach AJ, Stegman RC, Graham J, Kruger LP: Prophylaxis of aphakic cystoid macular edema without corticosteroids. A paired-comparison, placebo-controlled double-masked study. Ophthalmology 1990;97:1253-1258.
12. Almeida DR, Johnson D, Hollands H, et al: Effect of prophylactic nonsteroidal antiinflammatory drugs on cystoid macular edema assessed using optical coherence tomography quantification of total macular volume after cataract surgery. J Cataract Refract Surg 2008;34:64-69.
13. DeCroos FC, Afshari NA: Perioperative antibiotics and anti-inflammatory agents in cataract surgery. Curr Opin Ophthalmol 2008;19:22-26.
14. Rossetti L, Chaudhuri J, Dickersin K: Medical prophylaxis and treatment of cystoid macular edema after cataract surgery. The results of a meta-analysis. Ophthalmology 1998;105:397-405.
15. Nelson ML, Martidis A: Managing cystoid macular edema after cataract surgery. Curr Opin Ophthalmol 2003;14:39-43.
16. Sivaprasad S, Bunce C, Patel N: Non-steroidal anti-inflammatory agents for treating cystoid macular oedema following cataract surgery. Cochrane Database Syst Rev 2005;1:CD004239.
17. Rojas B, Zafirakis P, Christen W, Markomichelakis NN, Foster CS: Medical treatment of macular edema in patients with uveitis. Doc Ophthalmol 1999;97:399-407.
18. Flach AJ, Dolan BJ, Irvine AR: Effectiveness of ketorolac tromethamine 0.5% ophthalmic solution for chronic aphakic and pseudophakic cystoid macular edema. Am J Ophthalmol 1987;103:479-486.
19. Flach AJ, Jampol LM, Weinberg D, et al: Improvement in visual acuity in chronic aphakic and pseudophakic cystoid macular edema after treatment with topical 0.5% ketorolac tromethamine. Am J Ophthalmol 1991;112:514-519.
20. Haynes RC Jr, Murad F: Adrenocorticotropic hormone: adrenocortical steroids and their synthetic analogs: inhibitors of adrenocortical steroid biosynthesis; in Gilman AG, Goodman LS, Rall TW, Murad F (eds): Goodman and Gilman's The Pharmacological Basis of Therapeutics. New York, Macmillan, 1985, pp 1459-1489.
21. Nehmé A, Edelman J: Dexamethasone inhibits high glucose-, TNF-α-, and IL-1β-induced secretion of inflammatory and angiogenic mediators from retinal microvascular pericytes. Invest Ophthalmol Vis Sci 2008;49:2030-2038.
22. Othenin-Girard P, Borruat X, Bovey E, Pittet N, Herbort CP: Diclofenac-dexamethasone combination in treatment of postoperative inflammation: prospective double-blind study. Klin Monatsbl Augenheilkd 1992;200:362-366.
23. Edelman JL, Lutz D, Castro MR: Corticosteroids inhibit VEGF-induced vascular leakage in a rabbit model of blood-retinal and blood-aqueous barrier breakdown. Exp Eye Res 2005;80:249-258.
24. Wang K, Wang Y, Gao L, Li X, Li M, Guo J: Dexamethasone inhibits leukocyte accumulation and vascular permeability in retina of streptozotocin-induced diabetic rats via reducing vascular endothelial growth factor and intercellular adhesion molecule-1 expression. Biol Pharm Bull 2008;31:1541-1546.
25. Zhang X, Bao S, Lai D, Rapkins RW, Gillies MC: Intravitreal triamcinolone acetonide inhibits breakdown of the bloodretinal barrier through differential regulation of VEGF-A and its receptors in early diabetic rat retinas. Diabetes 2008;57:1026-1033.
26. Antonetti DA, Wolpert EB, DeMaio L, Harhaj NS, Scaduto RC Jr: Hydrocortisone decreases retinal endothelial cell water and solute flux coincident with increased content and decreased phosphorylation of occludin. J Neurochem 2002;80:667-677.
27. Nauck M, Roth M, Tamm M, Eickelberg O, Wieland H, Stulz P, Perruchoud AP: Induction of vascular endothelial growth factor by platelet-activating factor and platelet-derived growth factor is downregulated by corticosteroids. Am J Respir Cell Mol Biol 1997;16:398-406.
28. Ebrahem Q, Minamoto A, Hoppe G, Anand-Apte B, Sears JE: Triamcinolone acetonide inhibits IL-6- and VEGFinduced angiogenesis downstream of the IL-6 and VEGF receptors. Invest Ophthalmol Vis Sci 2006;47:4935-4941.
29. Leal EC, Manivannan A, Hosoya K, Terasaki T, Cunha-Vaz J, Ambrosio AF, Forrester JV: Inducible nitric oxide synthase isoform is a key mediator of leukostasis and blood-retinal barrier breakdown in diabetic retinopathy. Invest Ophthalmol Vis Sci 2007;48:5257-5265.
30. Mizuno S, Nishiwaki A, Morita H, Miyake T, Ogura Y: Effects of periocular administration of triamcinolone acetonide on leukocyte-endothelium interactions in the ischemic retina. Invest Ophthalmol Vis Sci 2007;48:2831-2836.
31. Reichenbach A, Wurm A, Pannicke T, Iandiev I, Wiedemann P, Bringmann A: Müller cells as players in retinal degeneration and edema. Graefes Arch Clin Exp Ophthalmol 2007;245:627-636.
32. Cox SN, Hay E, Bird AC: Treatment of chronic macular edema with acetazolamide. Arch Ophthalmol 1988;106:1190-1195.
33. Wistrand PJ, Schenholm M, Lönnerholm G: Carbonic anhydrase isoenzymes C in the human eye. Invest Ophthalmol Vis Sci 1986;27:419-428.
34. Wolfensberger TJ, Mahieu I, Jarvis-Evans J, et al: Membrane-bound carbonic anhydrase in human retinal pigment epithelium. Invest Ophthalmol Vis Sci 1994;35:3401-3407.
35. Wolfensberger TJ, Dmitriev AV, Govardovskii VI: Inhibition of membranebound carbonic anhydrase decreases subretinal pH and volume. Doc Ophthalmol 1999;97:261-271.
36. Miller SS, Steinberg RH: Active transport of ions across frog retinal pigment epithelium. Exp Eye Res 1977;25:235.
37. Marmor MF, Negi A: Pharmacologic modification of subretinal fluid absorption in the rabbit eye. Arch Ophthalmol 1986;104:1674-1677.
38. Wolfensberger TJ, Chiang RK, Takeuchi A, Marmor MF: Inhibition of membranebound carbonic anhydrase enhances subretinal fluid absorption and retinal adhesiveness. Graefes Arch Clin Exp Ophthalmol 2000;238:76-80.
39. Tsuboi S, Pederson JE: Experimental retinal detachment. 10. Effect of acetazolamide on vitreous fluorescein disappearance. Arch Ophthalmol 1985;103:1557-1558.
40. Yamamoto F, Steinberg RH: Effects of intravenous acetazolamide on retinal pH in the cat. Exp Eye Res 1992;54:711-718.
41. Antonetti DA, Barber AJ, Khin S, Lieth E, Tarbell JM, Gardner TW: Vascular permeability in experimental diabetes is associated with reduced endothelial occludin content: vascular endothelial growth factor decreases occludin in retinal endothelial cells. Penn State Retina Research Group. Diabetes 1998;47:1953-1959.
42. Antonetti DA, Barber AJ, Hollinger LA, Wolpert EB, Gardner TW: Vascular endothelial growth factor induces rapid phosphorylation of tight junction proteins occludin and zonula occluden 1. J Biol Chem 1999;274:23463-23467.
43. Lakshminarayanan S, Antonetti DA, Gardner TW, Tarbell JM: Effect of VEGF on retinal microvascular endothelial hydraulic conductivity: the role of NO. Invest Ophthalmol Vis Sci 2000;41:4256-4261.
44. DeMaio L, Antonetti DA, Scaduto RC Jr, Gardner TW, Tarbell JM: VEGF increases paracellular transport without altering the solvent-drag reflection coefficient. Microvasc Res 2004;68:295-302.
45. Harhaj NS, Felinski EA, Wolpert EB, Sundstrom JM, Gardner TW, Antonetti DA: VEGF activation of protein kinase C stimulates occludin phosphorylation and contributes to endothelial permeability. Invest Ophthalmol Vis Sci 2006;47:5106-5115.
46. Cordero Coma M, Sobrin L, Onal S, Christen W, Foster CS: Intravitreal bevacizumab for treatment of uveitic macular edema. Ophthalmology 2007;114:1574-1579.
47. Mason JO 3rd, Albert MA Jr, Vail R: Intravitreal bevacizumab (Avastin) for refractory pseudophakic cystoid macular edema. Retina 2006;26:356-357.
48. Rodriguez-Fontal M, Alfaro V, Kerrison JB, Jablon EP: Ranibizumab for diabetic retinopathy. Curr Diabetes Rev 2009;5:47-51.
49. Spaide RF, Chang LK, Klancnik JM, Yannuzzi LA, Sorenson J, Slakter JS, Freund KB, Klein R: Prospective study of intravitreal ranibizumab as a treatment for decreased visual acuity secondary to central retinal vein occlusion. Am J Ophthalmol 2009;147:298-306.
50. Starita C, Patel M, Katz B, Adamis AP: Vascular endothelial growth factor and the potential therapeutic use of pegaptanib (macugen) in diabetic retinopathy. Dev Ophthalmol 2007;39:122-148.
51. Arimura N, Otsuka H, Yamakiri K, Sonoda Y, Nakao S, Noda Y, Hashiguchi T, Maruyama I, Sakamoto T: Vitreous mediators after intravitreal bevacizumab or triamcinolone acetonide in eyes with proliferative diabetic retinopathy. Ophthalmology 2009;116:921-926.
52. van Kooij B, Rothova A, Rijkers GT, de Groot-Mijnes JD: Distinct cytokine and chemokine profiles in the aqueous of patients with uveitis and cystoid macular edema. Am J Ophthalmol 2006;142:192-194.
53. Curnow SJ, Murray PI: Inflammatory mediators of uveitis: cytokines and chemokines. Curr Opin Ophthalmol 2006;17:532-537.
54. Deuter CM, Koetter I, Guenaydin I, Stuebiger N, Zierhut M: Interferon alfa-2a: a new treatment option for long lasting refractory cystoid macular edema in uveitis? A pilot study. Retina 2006;26:786-791.
55. Becker MD, Heiligenhaus A, Hudde T, et al: Interferon as a treatment for uveitis associated with multiple sclerosis. Br J Ophthalmol 2005;89:1254-1257.
56. Nussenblatt RB, Palestine AG, Chan CC, Stevens G Jr, Mellow SD, Green SB: Randomized, double-masked study of cyclosporine compared to prednisolone in the treatment of endogenous uveitis. Am J Ophthalmol 1991;112:138-146.
57. Theodossiadis PG, Markomichelakis NN, Sfikakis PP: Tumor necrosis factor antagonists: preliminary evidence for an emerging approach in the treatment of ocular inflammation. Retina 2007;27:399-413.
58. Rothova A: Inflammatory cystoid macular edema. Curr Opin Ophthalmol 2007;18:487-492.
59. Kafkala C, Choi JY, Choopong P, Foster CS: Octreotide as a treatment for uveitic cystoid macular edema. Arch Ophthalmol 2006;124:1353-1355.
60. Fung WE: Vitrectomy for chronic aphakic cystoid macular edema. Results of a national, collaborative, prospective, randomized investigation. Ophthalmology 1985;92:1102-1111.
61. Lewis H, Abrams GW, Blumenkranz MS, Campo RV: Vitrectomy for diabetic macular traction and edema associated with posterior hyaloidal traction. Ophthalmology 1992;99:753-759.
62. Margherio RR, Trese MT, Margherio AR, Cartright K: Surgical management of vitreomacular traction syndromes. Ophthalmology 1989;96:1437-1445.
63. Stefánsson E, Novack RL, Hatchell DL: Vitrectomy prevents retinal hypoxia in branch retinal vein occlusion. Invest Ophthalmol Vis Sci 1990;31:284-289.
64. Holekamp NM, Shui YB, Beebe DC: Vitrectomy surgery increases oxygen exposure to the lens: a possible mechanism for nuclear cataract formation. Am J Ophthalmol 2005;139:302-310.
65. 2 levels. Exp Eye Res 2009;88:286-292.
66. Noma H, Funatsu H, Mimura T, Harino S, Hori S: Vitreous levels of interleukin-6 and vascular endothelial growth factor in macular edema with central retinal vein occlusion. Ophthalmology 2009;116:87-93.
67. Praidou A, Klangas I, Papakonstantinou E, Androudi S, Georgiadis N, Karakiulakis G, Dimitrakos S: Vitreous and serum levels of platelet-derived growth factor and their correlation in patients with proliferative diabetic retinopathy. Curr Eye Res 2009;34:152-161.
68. Stefánsson E: The therapeutic effects of retinal laser treatment and vitrectomy. A theory based on oxygen and vascular physiology. Acta Ophthalmol Scand 2001;79:435-440.
69. Stefánsson E: Ocular oxygenation and the treatment of diabetic retinopathy. Surv Ophthalmol 2006;4:364-380.